Within this landscape, immunotherapy has emerged as a beacon of promise, as underscored by the recent approval of a programmed cell death protein 1 (PD-1)-blocking antibody for the management of recurrent or metastatic disease (7). This evidence concerns the gene PDCD1 and metastatic neoplasm.